Home › Funds › Siren, L.L.C. › AMLX
Siren, L.L.C. position in AMLX
Amylyx Pharmaceuticals, Inc. · Health Care
Siren, L.L.C. reported holding 2,480,586 shares of AMLX (Amylyx Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$72.2M, representing 1.71% of its reported portfolio and ranking #17 among its reported holdings. Siren, L.L.C. has disclosed AMLX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s AMLX position evolved
Siren, L.L.C. first disclosed a stake in AMLX in Q1 2026 at 1,230,000 shares (US$17.1M). The position peaked in Q3 2026 at 2,480,586 shares, worth US$72.2M. Across 3 filings, Siren, L.L.C. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,480,586 shares valued at US$72.2M — an increase of 1,000,000 shares quarter over quarter.. Notable position changes include a 68% increase in Q3 2026 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.23M | $17.10M | New |
| Q2 2026 | 1.48M | $26.59M | Add |
| Q3 2026 | 2.48M | $72.19M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (Amylyx Pharmaceuticals, Inc.) is a Health Care company. 50 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Commodore Capital LP 5.65M sh · $101.47M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Almitas Capital LLC 974.88K sh · $17.51M · Q2 2026
- Jones Hill Capital LP 894.06K sh · $16.06M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- HighVista Strategies LLC 386.08K sh · $6.93M · Q2 2026
- STEMPOINT CAPITAL LP 384.30K sh · $6.90M · Q2 2026
FAQ
How long has Siren, L.L.C. held AMLX?
Siren, L.L.C. has disclosed AMLX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Siren, L.L.C.'s current position in AMLX?
As of Q3 2026, Siren, L.L.C. holds 2.48M shares of AMLX (Amylyx Pharmaceuticals, Inc.), valued at $72.19M, representing 1.71% of its reported portfolio and ranking #17.
Has Siren, L.L.C. been buying or selling AMLX?
In the latest 13F filing (Q3 2026), Siren, L.L.C. increased its position in AMLX. The position peaked in Q3 2026 at 2.48M shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.